BRII-296
Postpartum Depression
Phase 1Active
Key Facts
About Brii Biosciences
Founded in 2018, Brii Biosciences is a publicly traded biotech with a mission to address major public health challenges in infectious diseases and CNS disorders. Its core strategy involves in-licensing and co-developing clinical-stage assets, most notably achieving the first NMPA-approved COVID-19 neutralizing antibody combination in China. The company operates with a dual-US/China footprint, aiming to accelerate global innovation for patients in high-need markets.
View full company profileTherapeutic Areas
Other Postpartum Depression Drugs
| Drug | Company | Phase |
|---|---|---|
| ZURZUVAE (zuranolone) | Sage Therapeutics | Approved |
| Postpartum Depression Program | Biogen | Not Specified |
| Zuranolone (ZURZUVAE) | Neurocrine Biosciences | Marketed |